BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23055348)

  • 1. Population pharmacokinetic-pharmacodynamic analysis of neutropenia in cancer patients receiving PM00104 (Zalypsis(®)).
    González-Sales M; Valenzuela B; Pérez-Ruixo C; Fernández Teruel C; Miguel-Lillo B; Soto-Matos A; Pérez-Ruixo JJ
    Clin Pharmacokinet; 2012 Nov; 51(11):751-64. PubMed ID: 23055348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
    Hing J; Perez-Ruixo JJ; Stuyckens K; Soto-Matos A; Lopez-Lazaro L; Zannikos P
    Clin Pharmacol Ther; 2008 Jan; 83(1):130-43. PubMed ID: 17597713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil dynamics in peritoneal carcinomatosis patients treated with cytoreductive surgery and hyperthermic intraperitoneal oxaliplatin.
    Pérez-Ruixo C; Valenzuela B; Peris JE; Bretcha-Boix P; Escudero-Ortiz V; Farré-Alegre J; Pérez-Ruixo JJ
    Clin Pharmacokinet; 2013 Dec; 52(12):1111-25. PubMed ID: 23828617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patients.
    Pérez-Ruixo C; Valenzuela B; Fernández Teruel C; González-Sales M; Miguel-Lillo B; Soto-Matos A; Pérez-Ruixo JJ
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):15-24. PubMed ID: 21590449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.
    Massard C; Margetts J; Amellal N; Drew Y; Bahleda R; Stephens P; Armand JP; Calvert H; Soria JC; Coronado C; Kahatt C; Alfaro V; Siguero M; Fernández-Teruel C; Plummer R
    Invest New Drugs; 2013 Jun; 31(3):623-30. PubMed ID: 22688291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I pharmacokinetic study of PM00104 (Zalypsis) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors.
    Capdevila J; Clive S; Casado E; Michie C; Piera A; Sicart E; Carreras MJ; Coronado C; Kahatt C; Soto Matos-Pita A; Fernandez Teruel C; Siguero M; Cullell-Young M; Tabernero J
    Cancer Chemother Pharmacol; 2013 May; 71(5):1247-54. PubMed ID: 23455428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors.
    Salazar R; Calles A; Gil M; Durán I; García M; Hidalgo M; Coronado C; Alfaro V; Siguero M; Fernández-Teruel C; Prados R; Calvo E
    Invest New Drugs; 2014 Aug; 32(4):644-52. PubMed ID: 24535315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours.
    Yap TA; Cortes-Funes H; Shaw H; Rodriguez R; Olmos D; Lal R; Fong PC; Tan DS; Harris D; Capdevila J; Coronado C; Alfaro V; Soto-Matos A; Fernández-Teruel C; Siguero M; Tabernero JM; Paz-Ares L; de Bono JS; López-Martin JA
    Br J Cancer; 2012 Apr; 106(8):1379-85. PubMed ID: 22491421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.
    Sun W; O'Dwyer PJ; Finn RS; Ruiz-Garcia A; Shapiro GI; Schwartz GK; DeMichele A; Wang D
    J Clin Pharmacol; 2017 Sep; 57(9):1159-1173. PubMed ID: 28419480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.
    Joerger M; Kraff S; Huitema AD; Feiss G; Moritz B; Schellens JH; Beijnen JH; Jaehde U
    Clin Pharmacokinet; 2012 Sep; 51(9):607-17. PubMed ID: 22804749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semi-mechanistic model for neutropenia after high dose of chemotherapy in breast cancer patients.
    Ramon-Lopez A; Nalda-Molina R; Valenzuela B; Perez-Ruixo JJ
    Pharm Res; 2009 Aug; 26(8):1952-62. PubMed ID: 19488837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II clinical trial of PM00104 (Zalypsis(®)) in urothelial carcinoma patients progressing after first-line platinum-based regimen.
    Castellano DE; Bellmunt J; Maroto JP; Font-Pous A; Morales-Barrera R; Ghanem I; Suarez C; Martín Lorente C; Etxaniz O; Capdevila L; Coronado C; Alfaro V; Siguero M; Fernández-Teruel C; Carles J
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):857-67. PubMed ID: 24570330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic analysis of hyperthermic intraperitoneal oxaliplatin-induced neutropenia in subjects with peritoneal carcinomatosis.
    Valenzuela B; Nalda-Molina R; Bretcha-Boix P; Escudero-Ortíz V; Duart MJ; Carbonell V; Sureda M; Rebollo JP; Farré J; Brugarolas A; Pérez-Ruixo JJ
    AAPS J; 2011 Mar; 13(1):72-82. PubMed ID: 21210260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancers.
    Zhou H; Choi L; Lau H; Bruntsch U; Vries EE; Eckhardt G; Oosterom AT; Verweij J; Schran H; Barbet N; Linnartz R; Capdeville R
    J Clin Pharmacol; 2000 Mar; 40(3):275-83. PubMed ID: 10709156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetic-Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin.
    Fernández-Teruel C; Lubomirov R; Fudio S
    J Clin Pharmacol; 2021 Sep; 61(9):1206-1219. PubMed ID: 33914350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.
    Perez-Ruixo JJ; Zannikos P; Hirankarn S; Stuyckens K; Ludwig EA; Soto-Matos A; Lopez-Lazaro L; Owen JS
    Clin Pharmacokinet; 2007; 46(10):867-84. PubMed ID: 17854236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer.
    Tsushima T; Kasai H; Tanigawara Y
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):487-495. PubMed ID: 32930844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic-pharmacodynamic modelling of neutrophil response to G-CSF in healthy subjects and patients with chemotherapy-induced neutropenia.
    Melhem M; Delor I; Pérez-Ruixo JJ; Harrold J; Chow A; Wu L; Jacqmin P
    Br J Clin Pharmacol; 2018 May; 84(5):911-925. PubMed ID: 29318653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia.
    Hansson EK; Friberg LE
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):881-90. PubMed ID: 22057837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.